基本信息
views: 33
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Scott Bembenek is Founder and CEO of Denovicon Therapeutics. Denovicon seamlessly integrates AI, machine learning, and molecular modeling approaches (such as quantum chemistry, molecular dynamics, and free-energy methods) into its (hybrid) computational drug discovery platform. With it, a vast amount of chemical space (~10^27 molecules) is quickly and accurately triaged, with only the most desirable analogs being identified as early leads that are then ultimately transformed into clinical candidates.
Currently, we are focused on targets in the DNA damage response (DDR) pathways. In particular, we are progressing first-in-class molecules that selectively target PARP1 and PARP2 as therapeutics for a variety of cancers (in particular TNBC), neurodegenerative conditions, immune disorders, and cardiovascular diseases.
Research Interests
Papers共 53 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Mark S. Tichenor,John J. M. Wiener, Navin L. Rao,Genesis M. Bacani, Jianmei Wei,Charlotte Pooley Deckhut,J. Kent Barbay, Kevin D. Kreutter, Leon Chang, Kathleen W. Clancy,Heather E. Murrey, Weixue Wang,
semanticscholar(2020)
crossref(2019)
Hong Jia,Guangxiu Dai,Weiguo Su,Kun Xiao,Jianyang Weng,Zhulin Zhang,Qing Wang, Tianhai Yuan, Fuying Shi,Zheng Zhang, Wei Chen,Yang Sai,
Cited0Views0Bibtex
0
0
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn